SCHEMBL7063471

SCHEMBL7063471

CC(C)(C)[Si](OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](OCCO)[C@@H]1O)(c1ccccc1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 5/20 0.60
▸ NT5E P21589 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ DPP4 P27487 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ SLC28A1 O00337 1/20 0.48
▸ MAP3K7 O43318 1/20 0.48
▸ SLC28A2 O43868 1/20 0.48
▸ GAPDH P04406 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ADORA2A P29274 1/20 0.48
▸ ADORA2B P29275 1/20 0.48
▸ STAT6 P42226 1/20 0.48
▸ PI4KA P42356 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ PI4K2B Q8TCG2 1/20 0.48
▸ DOT1L Q8TEK3 1/20 0.48
▸ SLC29A1 Q99808 1/20 0.48
▸ PI4K2A Q9BTU6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7063474 1.00 ADORA1 (0.60) ADORA1NT5ESMN1; SMN2DPP4MEN1
SCHEMBL7066961 0.93 ADORA1 (0.57) ADORA1NT5ESMN1; SMN2RNASELDNPH1
SCHEMBL7066958 0.93 ADORA1 (0.57) ADORA1NT5ESMN1; SMN2RNASELDNPH1
SCHEMBL29832736 0.89 ADORA1 (0.71) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL11684182 0.89 ADORA1 (0.71) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL19128403 0.89 ADORA1 (0.71) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL11684174 0.89 ADORA1 (0.71) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL9850171 0.87 NT5E (0.66) ADORA1NT5ESMN1; SMN2DPP4MEN1
SCHEMBL9850169 0.87 NT5E (0.66) ADORA1NT5ESMN1; SMN2DPP4MEN1
SCHEMBL31670485 0.85 ADORA1 (0.61) ADORA1NT5ESMN1; SMN2DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624294-B2 Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside ISIS PHARMACEUTICALS, INC. 2003-09-23 — — US disclosed
US-20030078415-A1 Regioselective synthesis of 2'-O-modified nucleosides IONIS PHARMACEUTICALS, INC. 2003-04-24 — — US disclosed
US-6403779-B1 DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION ISIS PHARMACEUTICALS, INC. 2002-06-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078415-A1 Regioselective synthesis of 2'-O-modified nucleosides NSUN2, NT5C3B, RNGTT ADORA1 1499/4885NT5E 92/4885SMN1; SMN2 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback